NO953601L - Nukleinsyre som koder for en tumorreksjonsantigenforlöper - Google Patents

Nukleinsyre som koder for en tumorreksjonsantigenforlöper

Info

Publication number
NO953601L
NO953601L NO953601A NO953601A NO953601L NO 953601 L NO953601 L NO 953601L NO 953601 A NO953601 A NO 953601A NO 953601 A NO953601 A NO 953601A NO 953601 L NO953601 L NO 953601L
Authority
NO
Norway
Prior art keywords
tumor rejection
rejection antigen
nucleic acid
antigen precursor
acid encoding
Prior art date
Application number
NO953601A
Other languages
English (en)
Other versions
NO953601D0 (no
Inventor
Vincent Brichard
Aline Van Pel
Catia Traversari
Thomas Wolfel
Thierry Boon-Falleur
Etienne De Plaen
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO953601D0 publication Critical patent/NO953601D0/no
Publication of NO953601L publication Critical patent/NO953601L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ppfinnelsen vedrører nukleinsyre-molekyler som koder for en tumor-rejeksjonsantigenforløper. Nærmere bestemt psesseres tumor-rejeksjonsantigenforløperen, elleren", til minst ett tumor-rejeksjonsantigen, som pesenteres av HLA-A2-molekyler. Konsekvenser av iakttagelsen er også omtalt.
NO953601A 1993-03-18 1995-09-13 Nukleinsyre som koder for en tumorreksjonsantigenforlöper NO953601L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/032,978 US5620886A (en) 1993-03-18 1993-03-18 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1994/002487 WO1994021126A1 (en) 1993-03-18 1994-03-09 Nucleic acid coding for a tumor rejection antigen precursor

Publications (2)

Publication Number Publication Date
NO953601D0 NO953601D0 (no) 1995-09-13
NO953601L true NO953601L (no) 1995-10-31

Family

ID=21867896

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953601A NO953601L (no) 1993-03-18 1995-09-13 Nukleinsyre som koder for en tumorreksjonsantigenforlöper

Country Status (17)

Country Link
US (2) US5620886A (no)
EP (1) EP0690675B1 (no)
JP (1) JP3433322B2 (no)
CN (1) CN1072719C (no)
AT (1) ATE258379T1 (no)
AU (1) AU675707B2 (no)
CA (1) CA2158446C (no)
DE (2) DE69433518T4 (no)
DK (1) DK0690675T5 (no)
ES (1) ES2210252T3 (no)
FI (1) FI954360L (no)
NO (1) NO953601L (no)
NZ (1) NZ263348A (no)
PT (1) PT690675E (no)
TW (1) TW442568B (no)
WO (1) WO1994021126A1 (no)
ZA (1) ZA941812B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
AU727028B2 (en) * 1996-06-25 2000-11-30 Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
DE69839765D1 (de) 1997-01-27 2008-09-04 Ludwig Inst Cancer Res Lage-1 tumor-assozierte nukleinsäuren
US5879892A (en) * 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
WO1999037797A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Antigen-specific cells, methods of generating these cells and uses thereof
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7001999B1 (en) 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP3020413A1 (en) 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
EP2332971B1 (en) * 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CN101057145B (zh) 2004-06-23 2014-10-22 得克萨斯系统大学评议会 使用双粒子复合体检测生物分子的方法和组合物
EP1833506B1 (en) * 2004-12-29 2015-08-26 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
CA2612518A1 (en) 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
US7999088B2 (en) 2005-06-17 2011-08-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
EP2371850A3 (en) * 2005-06-17 2012-08-01 Mannkind Corporation Epitope analogues
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP2152890A1 (en) * 2007-05-23 2010-02-17 MannKind Corporation Multicistronic vectors and methods for their design
EP2224954B1 (en) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
JP6449338B2 (ja) 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Also Published As

Publication number Publication date
PT690675E (pt) 2004-06-30
EP0690675A4 (en) 1998-12-23
EP0690675A1 (en) 1996-01-10
EP0690675B1 (en) 2004-01-28
ATE258379T1 (de) 2004-02-15
FI954360A0 (fi) 1995-09-15
NO953601D0 (no) 1995-09-13
CN1093406A (zh) 1994-10-12
DE69433518D1 (de) 2004-03-04
CN1072719C (zh) 2001-10-10
US5620886A (en) 1997-04-15
WO1994021126A1 (en) 1994-09-29
ES2210252T3 (es) 2004-07-01
JPH08507693A (ja) 1996-08-20
ZA941812B (en) 1994-10-13
CA2158446C (en) 2009-01-06
JP3433322B2 (ja) 2003-08-04
NZ263348A (en) 1996-06-25
DE69433518T4 (de) 2009-07-23
DK0690675T5 (da) 2008-11-17
DK0690675T3 (da) 2004-06-01
FI954360A7 (fi) 1995-09-15
AU6399394A (en) 1994-10-11
AU675707B2 (en) 1997-02-13
CA2158446A1 (en) 1994-09-29
TW442568B (en) 2001-06-23
DE69433518T2 (de) 2004-06-24
FI954360L (fi) 1995-09-15
US5854203A (en) 1998-12-29

Similar Documents

Publication Publication Date Title
NO953601L (no) Nukleinsyre som koder for en tumorreksjonsantigenforlöper
NO955063D0 (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
MX9204661A (es) Compuestos intermedios derivados de eter y procedimiento para su preparacion.
IT8123284A0 (it) Gas.procedimento per la produzione di
ES513943A0 (es) "procedimiento para la fabricacion de recubrimientos curables por permeacion de vapor".
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2184896T3 (es) Procedimiento para la obtencion de ciclodepsipeptidos con 24 atomos en el anillo, que contienen acidos aril-lacticos substituidos.
DE59003144D1 (de) Destillationsanlage zur Herstellung von Wasserstoff-Peroxid.
ES477520A1 (es) Procedimiento para la preparacion de nuevas penicilinas.
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
DK0804467T3 (da) Isolerede, trunkerede nukleinsyremolekyler, som koder for GAGE-tumorafstødningsantigen
ES8706700A1 (es) Procedimiento para preparar un derivado de cefalosporina.
DE59509910D1 (de) Verfahren zur Herstellung von Alkylhydrogenchlorsilanen
DK0787124T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aminobenzonitriler
FR2608607B1 (fr) Procede de preparation de thienylethylamines et dithienylethylamines ainsi obtenues
ES8706148A1 (es) Un procedimiento para preparar nuevos derivados de carbapenem.
FR2357517A1 (fr) Procede de production d'halogenophenols
ES2038740T4 (es) Procedimiento de obtencion de compuestos guanidicos que comprenden un ion tetrafenilborato sustituido.
DK439082A (da) 4-acylamino-1-aza-adamantan-forbindelser samt fremgangsmaade til fremstilling deraf
PT1000067E (pt) Tiazolobenzo-heterociclos sua preparacao e medicamentos que os contem
MX9404783A (es) Procedimiento para la preparacion de erdosteina.
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE69109953D1 (de) Alfa-fluorocarbonsäurederivate als Zwischenprodukte zur Herstellung von Fungiziden.
BR0207953A (pt) Derivados de caloporosida, processos para a sua preparação e sua aplicação
MX9300053A (es) Procedimiento para la preparacion de 1,3,5-tris (4'-hidroxiaril) benceno.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application